Semaglutide shortage — CA supply status & alternatives

Semaglutide

ATC A10BJ06 · GLP-1 receptor agonist

🇦🇺 AUST R 308324 · Novo Nordisk Pharmaceuticals Pty Ltd

In shortage · Australia

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🌐 EU🇺🇸 US🇧🇪 BE🇵🇹 PT

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

🇦🇺 AUAEMPA$111.44DPMQ A$131.40details →

Product attributes reference data we hold

Active ingredient (INN)	Semaglutide
Brand names	Wegovy, Ozempic, Rybelsus
ATC level 5	A10BJ06
ATC level 4	A10BJ
Drug class	GLP-1 receptor agonist
Therapeutic category	Endocrine/Metabolic
Strength	0.25mg · 0.5mg · 1mg · 2mg · 3mg · 7mg · 14mg
Dosage form	solution for injection · tablet
Route of administration	subcutaneous · oral
Controlled substance	No
Marketing-authorisation holders	Novo Nordisk Pharmaceuticals Pty Ltd
Registrations on file	15
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

64 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Chengdu Brilliant Biopharmaceutical CO LTDSichuan Jisheng Biopharmaceutical CO LTDFujian Genohope Biotech LTDTianjin Asymchem Pharmaceuticals CO LTDHangzhou Zhongmei Huadong Pharmaceutical CO LTDAsymchem Life Science Tianjin CO LTD+58 more

Manufacturing countries: China, India, United States, Belgium, Switzerland, Malaysia, Taiwan · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇨🇦

Canada

HC · 11h ago

Critical

🇺🇸

United States

FDA MedWatch · just now

High

🇦🇺

Australia

TGA · 1h ago

High

🌐

EMA · 1d ago

High

🇵🇹

INFARMED · 2h ago

Medium

🇧🇪

FAMHP · 2h ago

Medium

🇳🇴

Norway

NOMA · 3d ago

Resolved

🇮🇹

Italy

AIFA · 7h ago

Resolved

Recalls official enforcement reports

🇺🇸

Semaglutide

Harbin Jixianglong Biotech Co., Ltd. · Feb 2026

Class IIdetails ↗

🇺🇸

Semaglutide

Harbin Jixianglong Biotech Co., Ltd. · Feb 2026

Class IIdetails ↗

🇺🇸

WEGOVY

Novo Nordisk Inc. · Dec 2025

Class IIdetails ↗

🇺🇸

WEGOVY

Novo Nordisk Inc. · Dec 2025

Class IIdetails ↗

🇺🇸

Semaglutide Injection

ProRx LLC · Oct 2025

Class IIdetails ↗

🇺🇸

Semaglutide Injection

ProRx LLC · Oct 2025

Class IIdetails ↗

Sources official regulators

🇺🇸

FDA MedWatch

verified just now

verify ↗

🇨🇦

verified just now

verify ↗

🇺🇸

FDA

verified 1h ago

verify ↗

🇦🇺

TGA

verified 1h ago

verify ↗

🇵🇹

INFARMED

verified 2h ago

verify ↗

🇧🇪

FAMHP

verified 2h ago

verify ↗

🇮🇹

AIFA

verified 7h ago

verify ↗

🇺🇸

FDA-FE

verified 7h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders15 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
Ozempic 0.25/	0.5 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Ozempic	1 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
RYBELSUS semaglutide	14 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
RYBELSUS semaglutide	3 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
RYBELSUS semaglutide	7 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy	0.25 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy	0.5 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy	1 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy	1.7 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy	2.4 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy FlexTouch	0.5 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy FlexTouch	1 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy FlexTouch	1.7 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy FlexTouch	2.4 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
Wegovy FlexTouch	0.25 mg	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.